Acadia pharmaceuticals announces trofinetide new drug application for the treatment of rett syndrome has been accepted for filing and review by u.s. fda

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that the u.s. food and drug administration (fda) has accepted for filing its new drug application (nda) of trofinetide for the treatment of rett syndrome. the fda has granted a priority review and assigned a pdufa (prescription drug user fee act) action date of march 12, 2023. the fda has also informed the company that at this time they are not planning to hold an advisory committee meeting. “we're pleased th
ACAD Ratings Summary
ACAD Quant Ranking